Fig. 3From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumabProgression-free survival curves (a) and overall survival curves (b) according to irAEs in RUGC patients treated with nivolumab irAEs, immune-related adverse events; MST, median survival time; RUGC, recurrent or unresectable advanced gastric cancerBack to article page